Multidrug-resistant transporter Mdr1p-mediated uptake of a novel antifungal compound

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 12, 2013, Pages 5931-5939

  Sun, Nuo ^a   Li, Dongmei ^a   Fonzi, William ^a   Li, Xin ^b   Zhang, Lixin ^c   Calderone, Richard ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

^c INSTITUTE OF MICROBIOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; FLUCONAZOLE; ITRACONAZOLE; MULTIDRUG RESISTANCE PROTEIN 1; 1,3 BENZODIOXOLE DERIVATIVE; FUNGAL PROTEIN; MOLECULAR LIBRARY; MULTIDRUG RESISTANCE PROTEIN; NSC156627; QUINOLIZINE DERIVATIVE; TRANSCRIPTION FACTOR;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLUS FUMIGATUS; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; DNA BINDING; GENE CONTROL; INVASIVE CANDIDIASIS; MOLECULE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; ANTIFUNGAL RESISTANCE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MICROBIAL SENSITIVITY TEST; MOLECULAR LIBRARY; PHARMACOLOGY; TRANSPORT AT THE CELLULAR LEVEL;

ANTIFUNGAL AGENTS; ASPERGILLUS FUMIGATUS; BENZODIOXOLES; BIOLOGICAL TRANSPORT; CANDIDA ALBICANS; DRUG RESISTANCE, FUNGAL; FLUCONAZOLE; FUNGAL PROTEINS; GENE EXPRESSION REGULATION, FUNGAL; MICROBIAL SENSITIVITY TESTS; P-GLYCOPROTEIN; QUINOLIZINES; SMALL MOLECULE LIBRARIES; TRANSCRIPTION FACTORS;

EID: 84887421426     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01504-13     Document Type: Article

References (49)

1. Brown GD, Denning DW, Gow NA, Levitz SM, Netea MG, White TC. 2012. Hidden killers: human fungal infections. Sci. Transl. Med. 4:165rv113. doi:10.1126/scitranslmed.3004404.
2. Chauhan N, Latge JP, Calderone R. 2006. Signalling and oxidant adaptation in Candida albicans and Aspergillus fumigatus. Nat. Rev. Microbiol. 4:435-444.
3. Miceli MH, Diaz JA, Lee SA. 2011. Emerging opportunistic yeast infections. Lancet Infect. Dis. 11:142-151.
4. Miller LG, Hajjeh RA, Edwards JE, Jr. 2001. Estimating the cost of nosocomial candidemia in the united states. Clin. Infect. Dis. 32:1110.
5. Gomez J, Garcia-Vazquez E, Espinosa C, Ruiz J, Canteras M, Hernandez-Torres A, Banos V, Herrero JA, Valdes M. 2010. Nosocomial candidemia at a general hospital: prognostic factors and impact of early empiric treatment on outcome (2002-2005). Med. Clin. (Barc.) 134:1-5.
6. Ostrosky-Zeichner L, Casadevall A, Galgiani JN, Odds FC, Rex JH. 2010. An insight into the antifungal pipeline: selected new molecules and beyond. Nat. Rev. Drug Discov. 9:719-727.
7. Alexander BD, Johnson MD, Pfeiffer CD, Jimenez-Ortigosa C, Catania J, Booker R, Castanheira M, Messer SA, Perlin DS, Pfaller MA. 2013. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin. Infect. Dis. 56:1724-1732.
8. White TC. 1997. Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob. Agents Chemother. 41:1482-1487.
9. White TC, Marr KA, Bowden RA. 1998. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin. Microbiol. Rev. 11:382-402.
10. Tsao S, Rahkhoodaee F, Raymond M. 2009. Relative contributions of the Candida albicans ABC transporters Cdr1p and Cdr2p to clinical azole resistance. Antimicrob. Agents Chemother. 53:1344-1352.
11. Anderson JB. 2005. Evolution of antifungal-drug resistance: mechanisms and pathogen fitness. Nat. Rev. Microbiol. 3:547-556.
12. Cowen LE, Anderson JB, Kohn LM. 2002. Evolution of drug resistance in Candida albicans. Annu. Rev. Microbiol. 56:139-165.
13. Cowen LE. 2008. The evolution of fungal drug resistance: modulating the trajectory from genotype to phenotype. Nat. Rev. Microbiol. 6:187-198.
14. Morschhauser J, Barker KS, Liu TT, Bla BWJ, Homayouni R, Rogers PD. 2007. The transcription factor Mrr1p controls expression of the MDR1 efflux pump and mediates multidrug resistance in Candida albicans. PLoS Pathog. 3:e164. doi:10.1371/journal.ppat.0030164.
15. Hiller D, Stahl S, Morschhauser J. 2006. Multiple cis-acting sequences mediate upregulation of the MDR1 efflux pump in a fluconazole-resistant clinical Candida albicans isolate. Antimicrob. Agents Chemother. 50: 2300-2308.
16. Rognon B, Kozovska Z, Coste AT, Pardini G, Sanglard D. 2006. Identification of promoter elements responsible for the regulation of MDR1 from Candida albicans, a major facilitator transporter involved in azole resistance. Microbiology 152:3701-3722.
17. White TC, Holleman S, Dy F, Mirels LF, Stevens DA. 2002. Resistance mechanisms in clinical isolates of Candida albicans. Antimicrob. Agents Chemother. 46:1704-1713.
18. Wirsching S, Michel S, Morschhauser J. 2000. Targeted gene disruption in Candida albicans wild-type strains: the role of the MDR1 gene in fluconazole resistance of clinical Candida albicans isolates. Mol. Microbiol. 36:856-865.
19. Hiller D, Sanglard D, Morschhauser J. 2006. Overexpression of the MDR1gene is sufficient to confer increased resistance to toxic compounds in Candida albicans. Antimicrob. Agents Chemother. 50:1365-1371.
20. Cowen LE, Nantel A, Whiteway MS, Thomas DY, Tessier DC, Kohn LM, Anderson JB. 2002. Population genomics of drug resistance in Candida albicans. Proc. Natl. Acad. Sci. U. S. A. 99:9284-9289.
21. Dunkel N, Blass J, Rogers PD, Morschhauser J. 2008. Mutations in the multi-drug resistance regulator MRR1, followed by loss of heterozygosity, are the main cause of MDR1 overexpression in fluconazole-resistant Candida albicans strains. Mol. Microbiol. 69:827-840.
22. Sun N, Fonzi W, Chen H, She X, Zhang L, Calderone R. 2013. Azole susceptibility and transcriptome profiling in Candida albicans mitochondrial electron transport chain complex I mutants. Antimicrob. Agents Chemother. 57:532-542.
23. Chen H, Calderone R, Sun N, Wang Y, Li D. 2012. Caloric restriction restores the chronological life span of the goa1 null mutant of Candida albicans in spite of high cell levels of ROS. Fungal Genet. Biol. 49:1023-1032.
24. Li D, Chen H, Florentino A, Alex D, Sikorski P, Fonzi WA, Calderone R. 2011. Enzymatic dysfunction of mitochondrial complex I of the Candida albicans goa1 mutant is associated with increased reactive oxidants and cell death. Eukaryot. Cell 10:672-682.
25. Cowen LE, Singh SD, Kohler JR, Collins C, Zaas AK, Schell WA, Aziz H, Mylonakis E, Perfect JR, Whitesell L, Lindquist S. 2009. Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease. Proc. Natl. Acad. Sci. U. S. A. 106:2818-2823.
26. Fuchs BB, O'Brien E, Khoury JB, Mylonakis E. 2010. Methods for using Galleria mellonella as a model host to study fungal pathogenesis. Virulence 1:475-482.
27. Franz R, Kelly SL, Lamb DC, Kelly DE, Ruhnke M, Morschhauser J. 1998. Multiple molecular mechanisms contribute to a stepwise development of fluconazole resistance in clinical Candida albicans strains. Antimicrob. Agents Chemother. 42:3065-3072.
28. Cannon RD, Lamping E, Holmes AR, Niimi K, Baret PV, Keniya MV, Tanabe K, Niimi M, Goffeau A, Monk BC. 2009. Efflux-mediated antifungal drug resistance. Clin. Microbiol. Rev. 22:291-321.
29. Mansfield BE, Oltean HN, Oliver BG, Hoot SJ, Leyde SE, Hedstrom L, White TC. 2010. Azole drugs are imported by facilitated diffusion in Candida albicans and other pathogenic fungi. PLoS Pathog. 6:e1001126. doi:10.1371/journal.ppat. 1001126.
30. Schubert S, Barker KS, Znaidi S, Schneider S, Dierolf F, Dunkel N, Aid M, Boucher G, Rogers PD, Raymond M, Morschhauser J. 2011. Regulation of efflux pump expression and drug resistance by the transcription factors Mrr1, Upc2, and Cap1 in Candida albicans. Antimicrob. Agents Chemother. 55:2212-2223.
31. Kumar R, Chadha S, Saraswat D, Bajwa JS, Li RA, Conti HR, Edgerton M. 2011. Histatin 5 uptake by Candida albicans utilizes polyamine transporters Dur3 and Dur31 proteins. J. Biol. Chem. 286:43748-43758.
32. Gbelska Y, Krijger JJ, Breunig KD. 2006. Evolution of gene families: the multidrug resistance transporter genes in five related yeast species. FEMS Yeast Res. 6:345-355.
33. Igarashi K, Kashiwagi K. 1999. Polyamine transport in bacteria and yeast. Biochem. J. 344:633-642.
34. Kaouass M, Audette M, Ramotar D, Verma S, De Montigny D, Gamache I, Torossian K, Poulin R. 1997. The STK2 gene, which encodes a putative Ser/Thr protein kinase, is required for high-affinity spermidine transport in Saccharomyces cerevisiae. Mol. Cell. Biol. 17:2994-3004.
35. Ryan O, Shapiro RS, Kurat CF, Mayhew D, Baryshnikova A, Chin B, Lin ZY, Cox MJ, Vizeacoumar F, Cheung D, Bahr S, Tsui K, Tebbji F, Sellam A, Istel F, Schwarzmuller T, Reynolds TB, Kuchler K, Gifford DK, Whiteway M, Giaever G, Nislow C, Costanzo M, Gingras AC, Mitra RD, Andrews B, Fink GR, Cowen LE, Boone C. 2012. Global gene deletion analysis exploring yeast filamentous growth. Science 337:1353-1356.
36. Lewis K. 2001. In search of natural substrates and inhibitors of MDR pumps. J. Mol. Microbiol. Biotechnol. 3:247-254.
37. Tegos G, Stermitz FR, Lomovskaya O, Lewis K. 2002. Multidrug pump inhibitors uncover remarkable activity of plant antimicrobials. Antimicrob. Agents Chemother. 46:3133-3141.
38. Holmes AR, Keniya MV, Ivnitski-Steele I, Monk BC, Lamping E, Sklar LA, Cannon RD. 2012. The monoamine oxidase A inhibitor clorgyline is a broad-spectrum inhibitor of fungal ABC and MFS transporter efflux pump activities which reverses the azole resistance of Candida albicans and Candida glabrata clinical isolates. Antimicrob. Agents Chemother. 56:1508-1515.
39. Tan KW, Li Y, Paxton JW, Birch NP, Scheepens A. 2013. Identification of novel dietary phytochemicals inhibiting the efflux transporter breast cancer resistance protein (BCRP/ABCG2). Food Chem. 138:2267-2274.
40. Uemura T, Tachihara K, Tomitori H, Kashiwagi K, Igarashi K. 2005. Characteristics of the polyamine transporter TPO1 and regulation of its activity and cellular localization by phosphorylation. J. Biol. Chem. 280: 9646-9652.
41. Braun BR, van Het Hoog M, d'Enfert C, Martchenko M, Dungan J, Kuo A, Inglis DO, Uhl MA, Hogues H, Berriman M, Lorenz M, Levitin A, Oberholzer U, Bachewich C, Harcus D, Marcil A, Dignard D, Iouk T, Zito R, Frangeul L, Tekaia F, Rutherford K, Wang E, Munro CA, Bates S, Gow NA, Hoyer LL, Kohler G, Morschhauser J, Newport G, Znaidi S, Raymond M, Turcotte B, Sherlock G, Costanzo M, Ihmels J, Berman J, Sanglard D, Agabian N, Mitchell AP, Johnson AD, Whiteway M, Nantel A. 2005. A human-curated annotation of the Candida albicans genome. PLoS Genet. 1:36-57.
42. Bambach A, Fernandes MP, Ghosh A, Kruppa M, Alex D, Li D, Fonzi WA, Chauhan N, Sun N, Agrellos OA, Vercesi AE, Rolfes RJ, Calderone R. 2009. Goa1p of Candida albicans localizes to the mitochondria during stress and is required for mitochondrial function and virulence. Eukaryot. Cell 8:1706-1720.
43. McDonough JA, Bhattacherjee V, Sadlon T, Hostetter MK. 2002. Involvement of Candida albicans NADH dehydrogenase complex I in filamentation. Fungal Genet. Biol. 36:117-127.
44. Shingu-Vazquez M, Traven A. 2011. Mitochondria and fungal pathogenesis: drug tolerance, virulence, and potential for antifungal therapy. Eukaryot. Cell 10:1376-1383.
45. Vellucci VF, Gygax SE, Hostetter MK. 2007. Involvement of Candida albicans pyruvate dehydrogenase complex protein X (Pdx1) in filamentation. Fungal Genet. Biol. 44:979-990.
46. Fonzi WA, Irwin MY. 1993. Isogenic strain construction and gene mapping in Candida albicans. Genetics 134:717-728.
47. Morio F, Loge C, Besse B, Hennequin C, Le Pape P. 2010. Screening for amino acid substitutions in the Candida albicans Erg11 protein of azolesusceptible and azole-resistant clinical isolates: new substitutions and a review of the literature. Diagn. Microbiol. Infect. Dis. 66:373-384.
48. MacCallum DM, Coste A, Ischer F, Jacobsen MD, Odds FC, Sanglard D. 2010. Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection. Antimicrob. Agents Chemother. 54:1476-1483.
49. Richards TS, Oliver BG, White TC. 2008. Micafungin activity against Candida albicans with diverse azole resistance phenotypes. J. Antimicrob. Chemother. 62:349-355.